Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
Phase 3 Recruiting
186 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
VELOCITY-Lung
Phase 2 Recruiting
270 enrolled
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
698 enrolled
IDeate-Prostate02
Phase 1/2 Recruiting
360 enrolled
MK-5684-01A
Phase 1/2 Recruiting
220 enrolled
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Phase 2 Recruiting
60 enrolled
MK-2400-001
Phase 3 Recruiting
1,440 enrolled
TroFuse-033
Phase 3 Recruiting
1,123 enrolled
KLK2-PASenger
Phase 3 Recruiting
800 enrolled
RASolve 301
Phase 3 Recruiting
420 enrolled
DE-01
Phase 3 Recruiting
600 enrolled
EmpowHER 208
Phase 2 Recruiting
125 enrolled
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
Phase 3 Recruiting
572 enrolled
ARTEMIA
Phase 3 Recruiting
363 enrolled
InavoPC
Phase 2 Recruiting
100 enrolled
MEVPRO-1
Phase 3 Recruiting
600 enrolled
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Phase 2 Recruiting
131 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Phase 1/2 Recruiting
366 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
Phase 3 Recruiting
540 enrolled
KEYNOTE-365
Phase 1/2 Recruiting
1,200 enrolled
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Phase 1 Recruiting
277 enrolled
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2 Recruiting
230 enrolled
TROPION-Lung17
Phase 3 Recruiting
400 enrolled
Fern-EC-01
Phase 3 Recruiting
480 enrolled
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer
Phase 3 Recruiting
740 enrolled
A Study of KK2269 in Adult Participants With Solid Tumors
Phase 1 Recruiting
101 enrolled
rechARge
Phase 3 Recruiting
960 enrolled
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Phase 1/2 Recruiting
594 enrolled
Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
51 enrolled
Magic-C002
Phase 3 Recruiting
446 enrolled
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
Phase 2 Recruiting
62 enrolled
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Phase 3 Recruiting
510 enrolled
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Phase 3 Recruiting
300 enrolled
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
660 enrolled
A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer
Phase 1/2 Recruiting
100 enrolled
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Phase 1 Recruiting
351 enrolled
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Phase 1/2 Recruiting
490 enrolled
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
Phase 1 Recruiting
180 enrolled
LuCa-MERIT-1
Phase 1 Recruiting
280 enrolled
KYANITE-1
Phase 1/2 Recruiting
250 enrolled
ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
460 enrolled
ECLIPSE
Phase 3 Recruiting
412 enrolled
VIRO-25
Phase 2 Recruiting
142 enrolled
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1/2 Recruiting
320 enrolled
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
Phase 3 Recruiting
544 enrolled
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Phase 3 Recruiting
400 enrolled
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma
Phase 3 Recruiting
508 enrolled